BHARAT Biotech, the Hyderabad-based biotechnology company, is targeting a 25% rise in revenues during the current fiscal. For the 2004-05 financial year, it reported revenues of Rs 41 crore.

Talking to ET, Bharat Biotech CMD Dr Krishna M Ella said that the growth driver for them would be the discovery of new molecules which would given them a platform for creating global products.

The focus would be on creating drugs that can treat diseases affecting the people residing in the developing countries. He said pharma MNCs were not keen on developing these kind of drugs as they do not have much of a "dollar value". Bharat Biotech will also soon enter the markets of South Africa and Malaysia with its vaccine range.